Maze Therapeutics (MAZE) Stock Price, News & Analysis

Company Overview

Maze Therapeutics, Inc. (NASDAQ: MAZE) is a clinical-stage biotechnology company dedicated to unlocking the power of human genetics to develop precision therapies for cardiometabolic and related diseases. Since its founding, the firm has combined large-scale genetic analysis with functional genomics and advanced computational biology to identify and validate novel drug targets that arise from naturally occurring human variants.

The company’s proprietary discovery platform integrates extensive population-scale genetic datasets, machine learning algorithms and laboratory assays to accelerate the translation of genetic insights into therapeutic candidates. This approach enables Maze to prioritize targets with strong human validation and to optimize small-molecule or biologic modalities with a higher probability of clinical success.

Maze’s development pipeline comprises multiple preclinical and IND-enabling programs addressing conditions such as dyslipidemia, nonalcoholic steatohepatitis and other metabolic disorders. The company collaborates with leading academic institutions, research consortia and industry partners to expand its target portfolio and to advance its most promising programs into early-stage clinical trials.

Headquartered in South San Francisco with research operations in California and Europe, Maze Therapeutics is guided by a management team of seasoned industry veterans. Its leadership brings deep expertise in genetics-based drug discovery, clinical development and regulatory strategy, positioning the company to deliver transformative therapies for patients with unmet medical needs.

Key Stats

• Today's Range: $16.12 to $17.41
• 50-Day Range: $9.06 to $17.06
• 52-Week Range: $6.71 to $17.41
• Volume: 130,376 shs
• Average Volume: 117,618 shs
• Market Capitalization: $747.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.50
• Consensus Rating: Buy

MAZE Stock Analysis - Frequently Asked Questions

How have MAZE shares performed this year?

Maze Therapeutics' stock was trading at $13.38 at the beginning of 2025. Since then, MAZE stock has increased by 27.5% and is now trading at $17.06.

How were Maze Therapeutics' earnings last quarter?

Maze Therapeutics, Inc. (NASDAQ:MAZE) posted its earnings results on Wednesday, May, 14th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.76) by $0.39.

When did Maze Therapeutics IPO?

Maze Therapeutics (MAZE) raised $140 million in an IPO on Friday, January 31st 2025. The company issued 8,750,000 shares at $16.00 per share.

When does Maze Therapeutics' lock-up period expire?

Maze Therapeutics's lock-up period expires on Wednesday, July 30th. Maze Therapeutics had issued 8,750,000 shares in its IPO on January 31st. The total size of the offering was $140,000,000 based on an initial share price of $16.00. After the end of Maze Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

How do I buy shares of Maze Therapeutics?

Shares of MAZE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MAZE
• Previous Symbol: NASDAQ:MAZE
• CIK: 1842295
• Web: N/A
• Phone: (650) 850-5070
• Fax: N/A
• Employees: 121
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Maze Therapeutics: $23.50
• High Price Target: $30.00
• Low Price Target: $17.00
• Potential Upside/Downside: +37.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.10
• Quick Ratio: 16.10

Sales & Book Value

• Annual Sales: $167.50 million
• Price / Sales: 4.46
• Cash Flow: $0.16 per share
• Price / Cash Flow: 104.58
• Book Value: ($7.11) per share
• Price / Book: -2.40

Miscellaneous

• Outstanding Shares: 43,797,000
• Free Float: N/A
• Market Cap: $747.18 million
• Optionable: N/A
• Beta: N/A